Climb Bio Inc., a biotechnology company focused on developing therapeutics for immune-mediated diseases, announced on May 19, 2025, the granting of an inducement equity award to a new employee under its 2025 Inducement Plan. This award, in line with Nasdaq Listing Rule 5635(c)(4), comprises a non-statutory stock option to purchase up to 120,000 shares of the company's common stock at an exercise price of $1.27 per share, matching the closing price on the grant date. The option, which has a ten-year term, vests over four years, with 25% becoming exercisable on the first anniversary of the employee's start date and the rest vesting in 36 equal monthly installments, contingent on ongoing employment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.